{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:08:33Z","timestamp":1758190113490,"version":"3.44.0"},"reference-count":14,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"<jats:sec>\n<jats:title>Background &amp; objectives<\/jats:title>\n<jats:p>Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) with considerable heterogeneity in clinical outcomes. Existing prognostic models, such as the MCL International Prognostic Index (MIPI), demonstrate limited applicability in the Indian population due to differences in demographic and clinical profiles. This study was designed to develop indigenous prognostic tools to predict the survival of MCL patients from India.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective analysis of 92 patients with MCL diagnosed and treated over the past decade. Clinical, laboratory, and treatment parameters were reviewed to identify predictors of survival outcomes. Two prognostic models, the AIIMS MCL Overall Survival (AMOS) and Event-Free Survival (AMES) scores, were developed using multivariate logistic regression. Model performance was evaluated using receiver operator characteristic (ROC) curve analysis, with stratification into risk categories based on empiric score cut-offs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>AMOS and AMES models demonstrated robust predictive performance with area under ROC curve values of 0.75 and 0.82, respectively. The AMOS score incorporated Eastern Co-operative Oncology Group performance status (ECOG PS) and splenomegaly to predict two yr overall survival, while the AMES score included ECOG PS, B-symptoms, advanced stage, and rituximab maintenance (RM) to predict two yr event-free survival. Risk stratification revealed significant survival differences, with a median overall survival of nine months in the high-risk AMOS group compared to 75.5 months in the low-risk group. Similar trends were observed for event-free survival.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Interpretation &amp; conclusions<\/jats:title>\n<jats:p>AMOS and AMES scores are novel indigenous MCL survival prediction models. They are effective, pragmatic tools for risk stratification of MCL patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijmr_106_2025","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:13:14Z","timestamp":1758089594000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AIIMS Mantle Cell Lymphoma Overall Survival (AMOS) &amp; AIIMS Mantle Cell Lymphoma Event-Free Survival (AMES) scores: Development of novel indigenous survival prediction models &amp; risk stratification for mantle cell lymphoma in the Indian population"],"prefix":"10.25259","volume":"162","author":[{"given":"Soumyadeep","family":"Datta","sequence":"first","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveet","family":"Wig","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivam","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"10.25259\/IJMR_106_2025\/ref-1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.25259\/IJMR_106_2025\/ref-2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: a population-based clinical study","volume":"14","author":"Velders","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJMR_106_2025\/ref-3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"key":"10.25259\/IJMR_106_2025\/ref-4","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the European mantle cell lymphoma network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJMR_106_2025\/ref-5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJMR_106_2025\/ref-6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.25259\/IJMR_106_2025\/ref-7","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, r-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"10.25259\/IJMR_106_2025\/ref-8","first-page":"4583","article-title":"Mantle cell lymphoma: a North Indian tertiary care centre experience","volume":"17","author":"Das","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.25259\/IJMR_106_2025\/ref-9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10238-021-00683-2","article-title":"Lymphoma subtypes in India: a tertiary care center review","volume":"21","author":"Jain","year":"2021","journal-title":"Clin Exp Med"},{"key":"10.25259\/IJMR_106_2025\/ref-10","first-page":"e16534","article-title":"Clinicopathological and immunohistochemical profile of mantle cell lymphoma: an institutional experience","volume":"13","author":"Mishra","year":"2021","journal-title":"Cureus"},{"key":"10.25259\/IJMR_106_2025\/ref-11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/sajc.sajc_60_18","article-title":"Profile of non-Hodgkin lymphoma: an Indian perspective","volume":"7","author":"Gogia","year":"2018","journal-title":"South Asian J Cancer"},{"key":"10.25259\/IJMR_106_2025\/ref-12","volume-title":"SEER Cancer Statistics Review, 1975-2013","author":"Howlader","year":"2015"},{"key":"10.25259\/IJMR_106_2025\/ref-13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.13486","article-title":"Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan","volume":"170","author":"Chihara","year":"2015","journal-title":"Br J Haematol"},{"key":"10.25259\/IJMR_106_2025\/ref-14","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/S1470-2045(17)30773-8","article-title":"Maintenance rituximab in mantle-cell lymphoma","volume":"18","author":"Burki","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/aiims-mantle-cell-lymphoma-overall-survival-amos-aiims-mantle-cell-lymphoma-event-free-survival-ames-scores-development-of-novel-indigenous-survival-prediction-models-risk-str\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/aiims-mantle-cell-lymphoma-overall-survival-amos-aiims-mantle-cell-lymphoma-event-free-survival-ames-scores-development-of-novel-indigenous-survival-prediction-models-risk-str\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:13:16Z","timestamp":1758089596000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/aiims-mantle-cell-lymphoma-overall-survival-amos-aiims-mantle-cell-lymphoma-event-free-survival-ames-scores-development-of-novel-indigenous-survival-prediction-models-risk-str\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":14,"alternative-id":["10.25259\/IJMR_106_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_106_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"89"}}